Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.56 |
| ▸ | BCL2 | P10415 | 5/20 | 0.56 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | RPA1 | P27694 | 4/20 | 0.47 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5271389 | 0.91 | MDM2 (0.48) | MDM2MCL1BCL2P4HTMMEN1 | |
| SCHEMBL5979572 | 0.89 | MDM2 (0.73) | MDM2MCL1BCL2P4HTMRPA1 | |
| SCHEMBL5269383 | 0.89 | MDM2 (0.57) | MDM2MCL1BCL2P4HTMRPA1 | |
| SCHEMBL5522053 | 0.88 | MDM2 (0.46) | MDM2MCL1BCL2P4HTMRPA1 | |
| SCHEMBL4923110 | 0.87 | MDM2 (0.62) | MDM2MCL1BCL2P4HTMRPA1 | |
| SCHEMBL5267572 | 0.86 | RPA1 (0.55) | MDM2MCL1BCL2RPA1 | |
| SCHEMBL27648473 | 0.82 | RPA1 (0.46) | MDM2MCL1BCL2RPA1MEN1 | |
| SCHEMBL4927623 | 0.81 | MDM2 (0.57) | MDM2MCL1BCL2P4HTMMEN1 | |
| SCHEMBL5267172 | 0.81 | PPP1CA (0.50) | MDM2MCL1BCL2RPA1MEN1 | |
| SCHEMBL5269418 | 0.81 | MDM2 (0.46) | MDM2MCL1BCL2P4HTMRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| CN-101001852-A | Pyrazole derivatives | DAIICHI SEIYAKU CO (JP) | 2007-07-18 | — | — | CN | disclosed |
| CN-1902191-A | Amidopyrazole derivative | DAIICHI SEIYAKU CO (JP) | 2007-01-24 | — | — | CN | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | MDM2 4288/4885MCL1 1451/4885BCL2 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.